From: Airway host-microbiome interactions in chronic obstructive pulmonary disease
Demographic and baseline clinical features | Healthy Controls (N = 16) | COPD Patients (N = 43) |
---|---|---|
Age, yearsa | 55.0 (8.8) | 65.0 (4.8) |
Gender, n (% Male) b | 11 (68.8) | 31 (72.1) |
Current Smoker, n (%) | 8 (50.0) | 16 (37.2) |
Number of cigarette packs per year | 34.4 (11.2) | 50.9 (28.2) |
GOLD Stage: I/II/III/IV, n (%) | NA | 2 (4.7)/19 (44.2)/16 (37.2)/6 (14.0) |
Inhaled steroid use, n (%) | NA | 33 (76.7) |
LABA use, n (%) | NA | 34 (79.1) |
LAMA use, n (%) | NA | 35 (81.4) |
Number of exacerbations per year | NA | 1.9 (1.4) |
CAT score | NA | 21.8 (8.3) |
SGRQ total score | NA | 49.0 (22.9) |
mMRC score | NA | 2.1 (1.2) |
Pre FEV1 (L) | 3.0 (0.7) | 1.1 (0.5) |
Pre FVC (L) | 4.1 (1.0) | 2.8 (0.9) |
Pre FEV1/FVC ratio | 0.73 (0.0) | 0.4 (0.1) |
Post FEV1 (L) | 3.1 (0.8) | 1.2 (0.6) |
Post FVC (L) | 4.0 (0.9) | 3.3 (1.0) |
Post FEV1/FVC ratio | 0.76 (0.0) | 0.4 (0.1) |